These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7713858)

  • 1. Fluoxetine-clomipramine interaction.
    Sternbach H
    J Clin Psychiatry; 1995 Apr; 56(4):171-2. PubMed ID: 7713858
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination.
    Simeon JG; Thatte S; Wiggins D
    Psychopharmacol Bull; 1990; 26(3):285-90. PubMed ID: 2274627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug treatment of obsessive-compulsive disorders--a comparative study of the effectiveness of clomipramine and fluoxetine].
    Volk S
    Fortschr Neurol Psychiatr; 1995 Jun; 63 Suppl 1():28-32. PubMed ID: 7635392
    [No Abstract]   [Full Text] [Related]  

  • 4. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment.
    Hollander E; DeCaria CM; Schneier FR; Schneier HA; Liebowitz MR; Klein DF
    J Clin Psychiatry; 1990 Mar; 51(3):119-23. PubMed ID: 2106515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buspirone in obsessive-compulsive disorder.
    Maruno CA; Hart LL
    Ann Pharmacother; 1992 Oct; 26(10):1248-51. PubMed ID: 1421651
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluvoxamine in obsessive-compulsive nonresponders to clomipramine or fluoxetine.
    Mattes JA
    Am J Psychiatry; 1994 Oct; 151(10):1524. PubMed ID: 8092352
    [No Abstract]   [Full Text] [Related]  

  • 7. Paranoid and aggressive behavior in two obsessive-compulsive adolescents treated with clomipramine.
    Alarcon RD; Johnson BR; Lucas JP
    J Am Acad Child Adolesc Psychiatry; 1991 Nov; 30(6):999-1002. PubMed ID: 1757451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive dyskinesia associated with fluoxetine.
    Sandler NH
    J Clin Psychiatry; 1996 Feb; 57(2):91. PubMed ID: 8591977
    [No Abstract]   [Full Text] [Related]  

  • 10. A predictive study of obsessive-compulsive disorder response to clomipramine.
    Alarcon RD; Libb JW; Spitler D
    J Clin Psychopharmacol; 1993 Jun; 13(3):210-3. PubMed ID: 8354737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacotherapy of moral or religious scrupulosity.
    Fallon BA; Liebowitz MR; Hollander E; Schneier FR; Campeas RB; Fairbanks J; Papp LA; Hatterer JA; Sandberg D
    J Clin Psychiatry; 1990 Dec; 51(12):517-21. PubMed ID: 2258366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B; Bonnet-Perrin E
    Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three cases of pharmacotherapy of obsessive-compulsive disorder in the elderly.
    Austin LS; Zealberg JJ; Lydiard RB
    J Nerv Ment Dis; 1991 Oct; 179(10):634-5. PubMed ID: 1919549
    [No Abstract]   [Full Text] [Related]  

  • 14. Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy.
    Jenike MA; Baer L; Greist JH
    J Clin Psychopharmacol; 1990 Apr; 10(2):122-4. PubMed ID: 2140372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug response assessed by the Modified Maudsley Obsessive-Compulsive Inventory.
    Dominguez RA; Jacobson AF; de la Gandara J; Goldstein BJ; Steinbook RM
    Psychopharmacol Bull; 1989; 25(2):215-8. PubMed ID: 2602515
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.
    Hollander E; Stein DJ; DeCaria CM; Saoud JB; Klein DF; Liebowitz MR
    Biol Psychiatry; 1993 May; 33(10):747-9. PubMed ID: 8353170
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-induced mania.
    Mundo E; Ronchi P; Bellodi L
    Hosp Community Psychiatry; 1993 Jul; 44(7):689-90. PubMed ID: 8354514
    [No Abstract]   [Full Text] [Related]  

  • 18. The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder.
    Browne M; Horn E; Jones TT
    Can J Psychiatry; 1993 May; 38(4):242-3. PubMed ID: 8518974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder.
    Jenike MA; Baer L; Buttolph L
    J Clin Psychiatry; 1991 Jan; 52(1):13-4. PubMed ID: 1988411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
    Hantouche EG; Bouhassira M; Lancrenon S
    Encephale; 2000; 26(6):73-83. PubMed ID: 11217541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.